Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunlin Zhuang

Showing results (11-20 of 141) with videos related to

Pageof 15
Sort By:
Medchemcomm|August 16, 2018
Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 functionChunlin Zhuang, Zhongli Wu, Chengguo Xing, et al.
Marine Drugs|April 3, 2021
Structural-Based Optimizations of the Marine-Originated Meridianin C as Glucose Uptake Agents by Inhibiting GSK-3βShuwen Han, Chunlin Zhuang, Wei Zhou, et al.
Expert Opinion on Therapeutic Patents|September 18, 2025
A patent review of MLKL modulators (2023 - present)Bo-Wen Wan, Cheng-Shi Jiang, Chunlin Zhuang
Acta Pharmaceutica Sinica. B|July 10, 2020
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty yearsChunlin Zhuang, Christophe Pannecouque, Erik De Clercq, et al.
Journal of Medicinal Chemistry|October 7, 2022
Natural Product-Inspired Targeted Protein Degraders: Advances and PerspectivesJiao Li, Zhenyu Cai, Xu-Wen Li, et al.
Journal of Pharmaceutical Analysis|April 24, 2019
Methodology of drug screening and target identification for new necroptosis inhibitorsPengchao Pan, Zhenyu Cai, Chunlin Zhuang, et al.
Journal of Medicinal Chemistry|March 7, 2018
Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug DesignLong Chen, Chunlin Zhuang, Junjie Lu, et al.
ACS Chemical Neuroscience|November 14, 2022
Role of Necroptosis in Central Nervous System DiseasesHongming Shao, Wenbin Wu, Pei Wang, et al.
Free Radical Biology & Medicine|July 31, 2020
Transcription factor NRF2 as a promising therapeutic target for Alzheimer's diseaseZhuo Qu, Jiachen Sun, Wannian Zhang, et al.
Bioorganic Chemistry|April 12, 2023
Structure optimization of an F-indole-chalcone (FC116) on 4-methoxyphenyl group and therapeutic potential against colorectal cancers with low cytotoxicityBolin Du, Xiaoxia Liu, Xin Luan, et al.
Pageof 15

Showing results (11-20 of 141) with videos related to

Sort By:
Pageof 15
Medchemcomm|August 16, 2018
Small molecules inhibiting Keap1-Nrf2 protein-protein interactions: a novel approach to activate Nrf2 functionChunlin Zhuang, Zhongli Wu, Chengguo Xing, et al.
Marine Drugs|April 3, 2021
Structural-Based Optimizations of the Marine-Originated Meridianin C as Glucose Uptake Agents by Inhibiting GSK-3βShuwen Han, Chunlin Zhuang, Wei Zhou, et al.
Expert Opinion on Therapeutic Patents|September 18, 2025
A patent review of MLKL modulators (2023 - present)Bo-Wen Wan, Cheng-Shi Jiang, Chunlin Zhuang
Acta Pharmaceutica Sinica. B|July 10, 2020
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty yearsChunlin Zhuang, Christophe Pannecouque, Erik De Clercq, et al.
Journal of Medicinal Chemistry|October 7, 2022
Natural Product-Inspired Targeted Protein Degraders: Advances and PerspectivesJiao Li, Zhenyu Cai, Xu-Wen Li, et al.
Journal of Pharmaceutical Analysis|April 24, 2019
Methodology of drug screening and target identification for new necroptosis inhibitorsPengchao Pan, Zhenyu Cai, Chunlin Zhuang, et al.
Journal of Medicinal Chemistry|March 7, 2018
Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug DesignLong Chen, Chunlin Zhuang, Junjie Lu, et al.
ACS Chemical Neuroscience|November 14, 2022
Role of Necroptosis in Central Nervous System DiseasesHongming Shao, Wenbin Wu, Pei Wang, et al.
Free Radical Biology & Medicine|July 31, 2020
Transcription factor NRF2 as a promising therapeutic target for Alzheimer's diseaseZhuo Qu, Jiachen Sun, Wannian Zhang, et al.
Bioorganic Chemistry|April 12, 2023
Structure optimization of an F-indole-chalcone (FC116) on 4-methoxyphenyl group and therapeutic potential against colorectal cancers with low cytotoxicityBolin Du, Xiaoxia Liu, Xin Luan, et al.
Pageof 15